Robert Malenka Sells 6,524 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,524 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $18.65, for a total transaction of $121,672.60. Following the completion of the transaction, the director owned 393,147 shares in the company, valued at $7,332,191.55. This represents a 1.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Maplight Therapeutics Stock Down 4.8%

NASDAQ:MPLT opened at $17.69 on Friday. The company has a market cap of $802.60 million and a price-to-earnings ratio of -0.48. The firm’s fifty day moving average price is $17.62. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Leerink Partners began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Finally, Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.